e7 tcr transduced pbl cells
Cell therapyexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 21, 2016 (NCT02858310)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 2
- Anus Neoplasms · Phase 2
- Carcinoma · Phase 2
- Carcinoma in Situ · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Cervical Intraepithelial Neoplasia · Phase 1
- Neoplasms · Phase 2
- Neoplasms, Squamous Cell · Phase 2
- Oropharyngeal Neoplasms · Phase 2
- Papillomavirus Infections · Phase 2
- Penile Neoplasms · Phase 2
- Rectal Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Vaginal Neoplasms · Phase 2
- Vulvar Diseases · Phase 2
- Vulvar Neoplasms · Phase 2
Mechanism of action
- Human papillomavirusImmunity, passive
Human papillomavirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- e7 tcr transduced pbl cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05686226 | Phase 2 | Mar 7, 2023 | Rutgers University |
| NCT05639972 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2023 | National Cancer Institute (NCI), Rutgers University |
| NCT04476251 | Early Phase 1 (Phase 1) | Jan 8, 2021 | National Cancer Institute (NCI) |
| NCT04411134 | Phase 1 | Jun 5, 2020 | National Cancer Institute (NCI) |
| NCT04044950 | Phase 2 | Aug 8, 2019 | National Cancer Institute (NCI) |
| NCT04015336 | Phase 2 | Jul 31, 2019 | National Cancer Institute (NCI) |
| NCT03937791 | Phase 2 | Jun 10, 2019 | National Cancer Institute (NCI) |
| NCT02858310 | Phase 1 | Jul 21, 2016 | National Cancer Institute (NCI) |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 7 | 6 | 2 | 2016 |
| Rutgers University | Academic/Hospital | 2 | 2 | 1 | 2023 |
2 organizations
Page 1 / 1